Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study
Table 3
Comparison of changes in continuous variables between IVZ dose at baseline and up to 12 weeks visit using Repeated-Measures ANOVA with nesting.